Latest Asx Companies News

Hanwha Group claims US approval to fully own Austal, but independent checks suggest a narrower green light. Australian regulators still hold the final say on foreign ownership.

Integral Diagnostics has announced the planned retirement of CEO Dr Ian Kadish at the end of FY26, with an international search underway for his successor. The transition comes as the company focuses on integrating its recent merger with Capitol Health.

Develop Global has commenced concentrate production and cashflow at its Woodlawn copper/zinc mine, marking a significant milestone in its strategy to become a leading ASX copper and base metals company.

Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.

Asara Resources assures investors its Kada Gold Project permits remain intact despite Guinea’s recent revocation of over 120 exploration permits. Drilling has already commenced, signaling continued progress.

4DMedical has submitted its CT:VQ lung imaging technology for FDA clearance, aiming to disrupt the $1 billion US nuclear lung scan market with a non-nuclear, lower-cost alternative. Clinical studies show CT:VQ matches or exceeds existing nuclear imaging in accuracy and patient experience.

Microba Life Sciences reveals preliminary data from over 4,600 MetaXplore GI Plus tests showing significant clinical findings in the majority of patients, with two-thirds reporting symptom improvements following test-guided care.

GWA Group Limited has announced a fully franked ordinary dividend of AUD 0.075 per share for the half-year ending December 2024, signaling steady shareholder returns.

Micro-X Ltd has secured a $6 million contract extension from the U.S. Department of Homeland Security to develop and test additional self-screening airport security checkpoints, marking a significant step forward in its innovative security technology program.

Sandfire Resources Limited has announced the release date for its December 2024 half-year financial results, scheduled for February 20, 2025, accompanied by a live teleconference and webcast for investors.

Nyrada has secured ethics approval to begin its first-in-human Phase Ia trial of NYR-BI03, a promising neuro- and cardioprotective drug candidate. Recruitment starts soon, with dosing expected by March and results due in Q3 2025.

Mayfield Group Holdings has declared a $5 million special dividend alongside its interim payout, signaling robust financial health and confidence in sustained growth.